Published in final edited form as:

Microbiol Spectr. 2016 February ; 4(1): . doi:10.1128/microbiolspec.VMBF-0017-2015.

Evolution of Bacterial Pathogens within the Human Host

Kimberly A. Bliven and Anthony T. Maurelli[#]

Department of Microbiology and Immunology, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, Maryland 20814, USA

Abstract

Selective pressures within the human host, including interactions with innate and adaptive immune responses, exposure to medical interventions such as antibiotics, and competition with commensal microbiota all facilitate the evolution of bacterial pathogens. In this chapter, we present examples of pathogen strategies which emerged as a result of selective pressures within the human host niche, and discuss the resulting co-evolutionary ‘arms race’ between these organisms. In bacterial pathogens, many of the genes responsible for these strategies are encoded on mobile pathogenicity islands (PAIs) or plasmids, underscoring the importance of horizontal gene transfer (HGT) in the emergence of virulent microbial species.

INTRODUCTION

The success or failure of a pathogen is entirely dependent on its ability to survive, reproduce, and spread to a new host or environment. Host immune systems, predators, microbial competitors, parasites, and environmental resource limitations all exert selective pressures that shape the genomes of microbial populations (1). Host evolutionary fitness, meanwhile, is reliant on its capability to survive and reproduce; the host must effectively curtail diseases that weaken either of these abilities.

Dawkins *et al.* (1979) suggest that the conflicting drives between host and pathogen have led to an evolutionary arms race, where an asymmetric ‘attack-defense’ strategy has come into play (2). At the basic level, this concept suggests that when a host evolves new defenses to thwart a pathogen’s attack, the pathogen is forced to adapt a more impressive attack strategy to penetrate the heightened defenses. In response, the host must once again develop new defenses to cope with the new attack mechanism, and the cycle continues. Evolutionarily fit pathogens, which are able to survive, replicate, and spread effectively within the host, have an improved chance of passing their genes on to the next generation. Similarly, host genotypes are more likely to persist within the population if those particular individuals are more capable of controlling or resisting infection. Evolution, therefore, is driven by positive directional selection in the ‘arms race’ model; eventually, beneficial alleles should become fixed in a population. Another model favors frequency-dependent (balancing) selection, a

[#]**Corresponding author:** Anthony T. Maurelli, Department of Microbiology and Immunology, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, anthony.maurelli@usuhs.edu, Phone: 1 301 295 3415, Fax: 1 301 295 1545.

process that maintains rare alleles and therefore preserves polymorphic diversity within a population (3). Simply put, allele fixation is prevented because different bacterial alleles confer distinct advantages to the pathogen in the presence of different host alleles. Evidence exists within nature for both directional and frequency-dependent selection, and both types probably occur in bacterial populations.

In this chapter, we explore the host-pathogen interface and offer examples of pathogen adaptation in response to common host selective pressures (Table 1). Although we will focus our attention exclusively on bacterial pathogens within the human host, many of the concepts discussed in this review are readily applicable to other organisms, such as viruses, parasites, and fungi, which can infect a wide range of hosts including plants, animals, and amoeba (4-6).

As a final note, much of the evidence presented here to support presumed evolutionary events is either speculation from what is currently known or suspected about host and microbial biology, or the result of artificial laboratory-induced evolution during serial passaging of bacterial strains. Due to the sheer enormity of evolutionary timescales, defining the precise origins of and factors driving natural evolutionary events is often a difficult undertaking.

ANTAGONISTIC PLEIOTROPY AND THE FITNESS COST/BENEFIT ANALYSIS

At the most basic level, the theory of natural selection stipulates that, within a bacterial population, beneficial traits will be conserved (selected for), and deleterious traits eventually discarded (selected against). The actual evolutionary process is considerably more complex, however, due to the existence of genetic drift (the change in genetic diversity of a population due to random chance) and antagonistic pleiotropy.

Antagonistic pleiotropy is the concept that a single gene may control more than one phenotype, some of which may be beneficial to the organism, and some deleterious (7). Therefore, a gene may confer a selective advantage within one particular environment, but its expression could be detrimental within a different environment. Conservation of this gene ultimately is determined by the overall necessity of the gene to the organism's fitness. Bacterial pathogens may evolve mechanisms to neutralize the deleterious effects arising from antagonistic pleiotropy, while at the same time conserving the beneficial ones. Temporal regulation is a powerful tool to ensure that specific genes are only turned on when required, and turned off to prevent detrimental expression within a particular environment. Certain outer membrane proteins or systems are temporally regulated within the host, as they may provide a marker for recognition by the host immune system. Flagella expression, for example, is down-regulated by *Salmonella enterica* serovar Typhi *in vivo* to avoid activation of the host inflammatory response; however, outside the host, motility is likely important for the bacterium to seek out and scavenge nutrients from the environment (8). Other bacteria avoid the deleterious effects of a gene through gene inactivation; mutants that lose functionality of the gene once it becomes deleterious can out-compete the wild type parent strain, and eventually these mutants will dominate the population. *Pseudomonas*

aeruginosa, an opportunistic pathogen of cystic fibrosis patients, often switches to a mucoid phenotype *in vivo* as a result of overproduction of the exopolysaccharide alginate, which allows for the production of a bacterial biofilm in the lung (9, 10). MucA is a *P. aeruginosa* transmembrane protein that binds to and represses the sigma factor AlgU, which acts as the transcriptional activator of the alginate synthesis operon. AlgU activates AlgR, a suppressor of T3SS expression; when *mucA* is expressed, therefore, so are the T3SS genes. During acute infection, the T3SS plays an essential role in establishment of the bacterium within the respiratory tract. Once infection has been established, however, chronic infection appears to favor loss of T3SS and a switch to biofilm production (11). Both of these phenotypes are at least partially driven by various mutations in *mucA* which lead to derepression of AlgU, subsequent production of alginate, and suppression of the T3SS (9). Hauser (2009) speculates that loss of the T3SS protects the bacterium from eventual recognition by the host, as patients infected with *P. aeruginosa* develop antibodies against T3SS effector proteins; conversely, biofilm production likely allows for the persistence of the organism in the respiratory tract (11). Finally, certain bacteria simply tolerate deleterious fitness costs if the benefits of expressing the gene outweigh the negative effects. Antibiotic resistance mutations that allow bacteria to survive exposure to antimicrobials often come with a significant fitness disadvantage, for example, and secondary compensatory mutations in these strains may eventually arise to restore fitness rather than lose resistance (12).

THE IMPACT OF HOST-PATHOGEN INTERACTIONS ON MICROBIAL EVOLUTION

Inside the host, a successful pathogen will pilfer resources to survive, replicate, and eventually escape; concomitantly, the host will attempt to recognize and subsequently rid the body of the intruder. Co-evolution between host and pathogen naturally occurs as a result of these interactions (13). For practical purposes, we restrict our discussion to bacterial adaptation within the human host, but it is important to recognize that many of these concepts are applicable to pathogens of other hosts as well, such as plants or amoeba (14-16). As novel genetic variants within the human population emerge which prove more successful at preventing or overcoming infection, only pathogen variants that can surmount or avoid this new response will be successful. Within the last century, these natural host defenses, which take much longer to evolve than their microbial counter-parts, have been supplemented by man-made developments, such as antibiotics and modern medical interventions, which place added pressures on microbes to adapt (17). Host innate and adaptive immune responses and modern medical interventions are all selective pressures that contribute to pathogen evolution within the human host. Furthermore, microbial competition, either against other pathogens or commensal bacteria, also shapes pathogen genomes.

Bacteria have several advantages over the human host when it comes to evolution: first, their generation times are significantly shorter, leading to a much more rapid selection of beneficial alleles within a population. In conjunction with a shorter generation time, bacterial populations are typically larger, which may allow for greater genetic diversity from which to select. Lastly, many bacteria utilize horizontal gene transfer (HGT), which

accounts for the rapid spread of advantageous alleles between strains or even species (18). Virulence genes are commonly located on transferred pathogenicity islands (PAIs), segments of the genome associated with mobility elements, such as integrase genes or transposons, and a G+C content that differs from the remainder of the genome (19).

Host selective pressures: The innate and adaptive immune systems

The innate immune system is one of the first challenges encountered by the incoming pathogen following host contact. These diverse host defenses include physical barriers such as the mucosal epithelium, activation of the complement cascade, circulating antimicrobial peptides and cytokines, leukocytes, activation of the adaptive immune system, and sequestration of host nutrients away from pathogenic bacteria. In addition to evading innate immune mechanisms, the bacteria must also prevent or avoid adaptive immune responses which include B cell antibody production and T cell-mediated cytotoxicity. Pathogenic bacteria have evolved different approaches to overcome these host defenses.

In the human colon alone, intestinal microbiota concentrations average 10^{11} microorganisms per gram gut content, while 3×10^8 prokaryotes are thought to colonize the entire skin surface of the human adult (20). Consequently, bacteria that exploit more hostile and less frequently occupied niches may gain a selective edge in survival by avoiding sites of high competition. Natural structural barriers, however, typically prevent pathogens from engaging deeper host tissues. Physical blocks to infection include the intestinal and respiratory mucosa, the blood-brain barrier, the blood-CSF (cerebral spinal fluid) barrier, and the placental barrier (21). Most of these structures consist of a single layer of epithelial or endothelial cells bound closely together by tight junctions, adherens junctions, and desmosomes, which preclude bacteria from passively crossing (21, 22). Gastric and respiratory epithelia support an additional protective coating of mucus, which consists primarily of mucin glycoproteins and antimicrobial molecules (23). Mucin glycoproteins, produced by epithelial goblet cells and submucosal glands, can either remain cell-associated or undergo secretion into the mucosa, where they contribute to the viscous layer of mucus that can effectively trap microbes (24). Additionally, non-specific antimicrobials, such as defensins and lysozymes, and specific antimicrobials, such as IgG and secretory IgA, also limit the growth of microbes within the mucosa (23). Bacterial pathogens have developed numerous mechanisms to counteract these defenses.

The mucosal barrier can be broken down by mucinases such as the Pic enzyme of *Shigella* and Enteroaggregative *Escherichia coli* (EAEC) (25, 26). The *pic* gene is located on a chromosomal pathogenicity island in *Shigella*, and bounded upstream and downstream by insertion (IS)-like elements in EAEC, indicating a history of horizontal gene transfer in these pathogens (26). This potential gene transfer is intriguing as mucin degradation is also important for certain gastrointestinal commensals, which metabolize mucin glycoproteins for energy (27). It is tempting to speculate that these enzymes first evolved within human commensal bacteria as a means of nutrient acquisition, and only later spread to emerging pathogens to confer passage through the mucosal surface. Such a concept would support the hypothesis proposed by Rasko *et al.*, who suggest that commensal *E. coli* act as 'genetic sinks' for pathogenic *E. coli* isolates (28). Other pathogens, such as *Yersinia enterocolitica*

and *Vibrio cholerae*, avoid the thickest layers of the mucosal layer by targeting microfold (M) cells within the small intestine for uptake (23, 29). These specialized epithelial cells sample microorganisms residing in the intestinal lumen and present them to immune cells in the underlying lymphoid tissue. M cells are situated in the region of the epithelium known as the dome, which lacks mucin-secreting goblet cells (23).

Next, to breach the epithelial/endothelial barrier, pathogens must either actively cross using microbial-mediated processes, or opportunistically cross following disruption of barrier integrity. Some pathogens, such as *Bacteroides fragilis* and *Staphylococcus aureus*, directly break cell-cell junctions (30, 31). *B. fragilis*, an opportunistic pathogen, encodes a zinc-dependent metalloprotease toxin, BFT (*B. fragilis* enterotoxin), which cleaves the extracellular domain of E-cadherin, a host zonula adherens protein (30). Like the *pic* genes of *Shigella* and EAEC, the *bft* gene is carried on a pathogenicity island present in all enterotoxigenic *Bacteroides fragilis* strains (32). *S. aureus* induces bullous impetigo and staphylococcal scalded skin syndrome through the actions of three exfoliative toxins (ETs): ETA, ETB, and ETD (31). The ETs act as serine proteases which cleave human desmoglein 1, a transmembrane protein of desmosomes. The genes encoding these toxins are carried on different mobile genetic elements: the ETA gene is carried by a family of SaInt phages; the ETB gene is plasmid-encoded; and the ETD gene localizes to a 9 kB pathogenicity island (33, 34). Other pathogens, such as *Shigella*, *Salmonella*, and *Listeria*, transcytose through microfold (M) cells in the gut to gain access to the basolateral surface of the intestinal epithelium (35). Because these specialized host cells overlay Peyer's Patches (or gut-associated lymphoid tissue (GALT)), enteric bacteria transcytosed through M cells must then contend with macrophages, T lymphocytes, B lymphocytes, and dendritic cells.

As a putative example of counter-evolution, the human host may have developed mechanisms to avoid bacterial-mediated adhesion processes. *Helicobacter pylori* binds to the adhesion decoy Muc1, a mucin expressed on the surface of epithelial cells in the gastrointestinal tract (36). Muc1 is subsequently shed from the epithelial surface along with coupled bacteria, precluding long-term adhesion. Consequently, wild type mice have a five-fold lower *H. pylori* colonization burden than *Muc1*^{-/-} mice. Furthermore, human epidemiological studies have linked shorter Muc1 alleles to a higher probability of chronic gastritis progression, indicating that longer Muc1 alleles may confer a protective advantage to the host (37). Polymorphisms between human Muc1 alleles are largely restricted to the extracellular domain, which consists of a region of 30-90 tandem repeat units rich in serine and threonine. A study by Costa *et al.* (2002) demonstrated a significant positive association between the number of Muc1 tandem repeats and bacterial adherence for two strains of *H. pylori* *in vitro* (38). Longer Muc1 alleles probably evolved from shorter alleles via duplication events, and may have emerged to protect against pathogens such as *H. pylori* (39).

Complement cascade activation via the classical, lectin, and alternative pathways precedes the cleavage of C3 convertase into C3a, an anaphylatoxin, and C3b, which binds to the surface of microbes (otherwise known as opsonization) to promote the eventual clearance of bacteria through phagocytosis. Additionally, C3 convertase may convert to the lytic C5 convertase through addition of a C3b molecule. Pathogens have evolved mechanisms to

evade or block these processes (40). The *S. aureus* staphylococcal complement inhibitor (SCIN) protein stabilizes C3 convertase, preventing its cleavage into the active C3a and C3b fragments and attenuating anaphylatoxin activity and bacterial opsonization (41). Like many of the previously described pathogenicity factors, the gene encoding SCIN (*scn*) is located on a PAI (42). Rather than preventing C3 cleavage, the *Neisseria meningitidis* serine protease NalP splits C3 at a unique site, generating shorter C3a-like and longer C3b-like fragments (43). The C3b-like fragments are capable of binding *N. meningitidis*, but are rapidly degraded by host complement factors H (fH) and I (fI). Although the activity of the C3a-like fragment has not been determined, this fragment lacks the conserved C-terminal arginine residue found in wild type C3a that is essential for activity, and therefore this truncated version is likely inactive.

A final example of an innate host selective pressure is the sequestration of host resources or nutrients away from colonizing bacteria. Iron, an essential nutrient, is in short supply within the host, either sequestered away in host cells or stored as a complex in hemoglobin, which is inaccessible to most microbes (44). Correspondingly, pathogens have been forced to develop numerous mechanisms to scavenge host iron. Predictably, these systems are often iron-regulated, and their genes expressed following bacterial exposure to the low-iron environment of the human host. Certain surface-bound receptors can recognize iron-bound complexes, such as heme, transferrin, or lactoferrin. Additionally, the secreted bacterial siderophores, aerobactin and enterobactin, steal iron away from host transferrin and lactoferrin. *E. coli* strains can encode for both of these systems (45). Another putative example of 'arms race' co-evolution is the mammalian neutrophil gelatinase-associated lipoprotein (NGAL). NGAL directly binds the catecholate-type ferric siderophore complexed to iron, preventing bacterial iron sequestration and eventually exerting a bacteriostatic effect upon microbial populations (46). Some bacteria can even bypass this defense mechanism, however. Uropathogenic *E. coli* (UPEC) express the siderophore salmochelin, a glycosylated form of enterbactin resistant to the effects of NGAL (47).

If a pathogen manages to evade the innate immune system and can successfully compete with commensal bacteria, it must then elude host adaptive immune responses, including B- and T-cell lymphocytes (48). One bacterial strategy employed inhibits lymphocyte proliferation. The VacA cytotoxin of *H. pylori* blocks the activity of host calcineurin, leading to downstream attenuation of interleukin-2 (IL-2) transcription, a key mediator of T cell proliferation (49). Alternatively, bacteria can avoid the adaptive immune response altogether by mediating lymphocyte cell death. For example, *Shigella* induces B-cell apoptosis through the actions of its type three secretion system (T3SS) (50).

Host selective pressures: Antibiotic resistance

The rise of adaptive antibiotic resistance in bacteria is perhaps one of the most intensely studied examples of pathogen evolution in response to a specific selective pressure(s) (51). Blair (2015) separates adaptive resistance mechanisms into three primary categories: reduced drug permeability through changes in the bacterial membrane or the development of efflux pumps which quickly expel antimicrobials; mutations in antimicrobial targets to prevent binding; and enzymes which directly inactivate the antimicrobial agent itself (51).

Well-characterized efflux pumps include the multi-drug exporters discovered in the common food-borne pathogens *E. coli* (ArcAB-TolC), *S. enterica* (EmrAB), and *S. aureus* (QacA/B, NorA) (52). Linezolid, an oxazolidinone class antibiotic, binds the 23S rRNA subunit and blocks tRNA interactions with the A site to prevent peptide bond formation (53).

Unsurprisingly, linezolid resistance in a number of bacterial species has been linked to a G2576T mutation in the 23S rRNA gene, precluding linezolid binding at this site and providing an example of the second category of adaptive drug resistance (54, 55). Finally, enzymes such as beta-lactamases, aminoglycoside acyltransferases, and monooxygenases are responsible for the inactivating hydrolysis, group transfer, or oxidation of their respective antibiotics (56, 57). The rapid spread of antimicrobial resistance, and the rise of multi-drug resistance, is often linked to the HGT dissemination of genes encoding these enzymes, as many PAIs and plasmids have been shown to carry one or more drug resistance genes (58). Resistance adaptations often come with a fitness cost, however, which has been demonstrated both *in vivo* and *in vitro* (59).

Microbial competition

Competition between microbes undoubtedly plays a role in driving pathogen evolution, although this aspect of microbial evolution has not been widely studied and, except for a few examples, is still only very poorly understood. Bacteria can directly eliminate potential rivals through use of toxic peptides (bacteriocins) or through the utilization of type six secretion systems (T6SSs) (60, 61).

Bacteriocins are toxic peptides produced by bacteria which can target and kill neighboring microbes. Colicins, the most well-known members of this category, are produced by strains of *E. coli*, although bacteriocins have been described in a wide variety of bacteria, including *S. aureus*, *Pseudomonas pyogenes*, *Yersinia pestis*, and *Serratia marcescens* (61, 62). In *E. coli*, colicins exhibit a number of different modes of action. Pore-forming colicins, such as colicin A, can insert into the inner membranes of susceptible bacteria to create ion channels (63). Nuclease colicins, such as colicins E9 and E3, translocate across the outer and inner membranes of a susceptible bacterium to the cytoplasm, where they function as DNases (E9) or RNases (E3) (64, 65). Lastly, colicin M, a unique member of the colicin family, blocks peptidoglycan biosynthesis by degrading undecaprenyl phosphate-linked peptidoglycan precursors. These lipid-anchored intermediates are critical for the transport of peptidoglycan subunits across the cytoplasmic membrane (66, 67). To protect their own population against the harmful effects of these toxic peptides, the producers of colicins must concomitantly express immunity proteins, which block the action of their respective colicins. Immunity proteins of pore-forming colicins sit in the inner membrane and block pore-forming colicins from inserting into the bacterial membrane. Nuclease colicin immunity proteins bind to DNase or RNase colicins to prevent their enzymatic activity, and the immunity protein Cmi binds colicin M to render it catalytically inactive (61, 68). Competing bacteria can acquire these immunity proteins via HGT, providing protection against *E. coli* colicin toxicity. For example, *Shigella*, which does not produce the pore-forming colicin V, nevertheless encodes an immunity protein on its SHI-2 PAI, which protects against colicin V produced by strains of *E. coli* (69, 70).

The recently-discovered T6SSs of Gram-negative bacteria are responsible for the direct delivery of effector proteins into neighboring eukaryotic or bacterial cells, resulting in the death of host cells or the lysis of potential microbial competitors (71). VgrG1, an ADP-ribosyltransferase, is secreted from the *Aeromonas hydrophila* T6SS into host cells, where it disrupts the actin cytoskeleton and induces host cell apoptosis (72). Most of the described T6SS effectors, however, have been shown to target other microbes. The T6S exported proteins 1 and 3 (Tse1 and Tse3) of *P. aeruginosa* exhibit amidase and muramidase activity, respectively, against bacterial peptidoglycan (73). *P. aeruginosa* also encodes type VI lipase effector (Tle) proteins, which degrade the bacterial phospholipid phosphatidylethanolamine (74). In *Dickeya dadantii*, the Rhs (rearrangement hotspots) proteins RhsA and RhsB are secreted through the T6SS and function as toxic endonucleases in susceptible bacteria. While *D. dadantii* is a plant pathogen, the human pathogen *S. marcescens* also expresses a T6SS-secreted Rhs-family protein, although its function is yet unknown (75, 76). Similar to the colicin proteins, pathogens which encode a T6SS must also express immunity proteins to prevent self-killing. *P. aeruginosa* encodes T6S immunity 1 and 3 (Tsi1 and Tsi3) proteins, which interact with and inactivate Tse1 and Tse3 through mechanisms that are not yet understood (73).

Intriguingly, T6SSs may also be effective tools for gene acquisition via HGT. In *V. cholerae*, the T6SS is co-regulated with competence genes by the regulator TfoX, and transformation events are dependent upon the presence of an active T6SS (77). Borgeaud *et al.* (2015) suggest that following activation of TfoX, both competence and T6SS systems are expressed and assembled. After T6SS-mediated lysis of neighboring cells, DNA is released to the extracellular space, where it can then transform the competent bacterium (77).

CONCLUDING REMARKS

Bacterial pathogens within the human host are exposed to a vast variety of different selective pressures which shape bacterial genomes and drive the evolution of novel virulence factors. Concomitantly, human genomes also evolve as a result of these interactions, leading to a genetic ‘arms race’ between pathogens and their hosts. In bacteria, horizontal gene transfer (HGT) can enhance this process by allowing for the rapid dissemination of potentially beneficial alleles across strains or even species.

LITERATURE CITED

1. Toft C, Andersson SG. Evolutionary microbial genomics: insights into bacterial host adaptation. *Nature reviews Genetics*. 2010; 11(7):465–75.
2. Dawkins R, Krebs JR. Arms races between and within species. *Proceedings of the Royal Society of London Series B, Biological sciences*. 1979; 205(1161):489–511.
3. Woolhouse ME, Webster JP, Domingo E, Charlesworth B, Levin BR. Biological and biomedical implications of the co-evolution of pathogens and their hosts. *Nature genetics*. 2002; 32(4):569–77. [PubMed: 12457190]
4. Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. *Cell host & microbe*. 2010; 7(6):440–51. [PubMed: 20542248]
5. Mideo N. Parasite adaptations to within-host competition. *Trends in parasitology*. 2009; 25(6):261–8. [PubMed: 19409846]

6. Cooney NM, Klein BS. Fungal adaptation to the mammalian host: it is a new world, after all. *Current opinion in microbiology*. 2008; 11(6):511–6. [PubMed: 18955154]
7. Williams GC. Pleiotropy, natural selection, and the evolution of senescence. *Evolution; international journal of organic evolution*. 1957; 11(4):398–411.
8. Salazar-Gonzalez RM, Srinivasan A, Griffin A, Muralimohan G, Ertelt JM, Ravindran R, Vella AT, McSorley SJ. *Salmonella* flagellin induces bystander activation of splenic dendritic cells and hinders bacterial replication in vivo. *Journal of immunology*. 2007; 179(9):6169–75.
9. Wu W, Badrane H, Arora S, Baker HV, Jin S. MucA-mediated coordination of type III secretion and alginate synthesis in *Pseudomonas aeruginosa*. *Journal of bacteriology*. 2004; 186(22):7575–85. [PubMed: 15516570]
10. Boucher JC, Yu H, Mudd MH, Deretic V. Mucoid *Pseudomonas aeruginosa* in cystic fibrosis: characterization of *muc* mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. *Infection and immunity*. 1997; 65(9):3838–46. [PubMed: 9284161]
11. Hauser AR. The type III secretion system of *Pseudomonas aeruginosa*: infection by injection. *Nature reviews Microbiology*. 2009; 7(9):654–65. [PubMed: 19680249]
12. Schulz zur Wiesch P, Engelstadter J, Bonhoeffer S. Compensation of fitness costs and reversibility of antibiotic resistance mutations. *Antimicrobial agents and chemotherapy*. 2010; 54(5):2085–95. [PubMed: 20176903]
13. Morgan, AD.; Koskella, B. Coevolution of Host and Pathogen. In: Tibayreng, M., editor. *Genetics and Evolution of Infectious Diseases*. Elsevier; Burlington, MA: 2011. p. 147–71.
14. Langridge GC, Fookes M, Connor TR, Feltwell T, Feasey N, Parsons BN, Seth-Smith HM, Barquist L, Stedman A, Humphrey T, Wigley P, Peters SE, Maskell DJ, Corander J, Chabalgoity JA, Barrow P, Parkhill J, Dougan G, Thomson NR. Patterns of genome evolution that have accompanied host adaptation in *Salmonella*. *Proceedings of the National Academy of Sciences of the United States of America*. 2015; 112(3):863–8. [PubMed: 25535353]
15. Kemen AC, Agler MT, Kemen E. Host-microbe and microbe-microbe interactions in the evolution of obligate plant parasitism. *The New phytologist*. 2015 doi: 10.1111/nph.13284.
16. Price CT, Richards AM, Von Dwingelo JE, Samara HA, Abu Kwaik Y. Amoeba host-*Legionella* synchronization of amino acid auxotrophy and its role in bacterial adaptation and pathogenic evolution. *Environmental microbiology*. 2014; 16(2):350–8. [PubMed: 24112119]
17. Davies J, Davies D. Origins and evolution of antibiotic resistance. *Microbiology and molecular biology reviews : MMBR*. 2010; 74(3):417–33. [PubMed: 20805405]
18. Wiedenbeck J, Cohan FM. Origins of bacterial diversity through horizontal genetic transfer and adaptation to new ecological niches. *FEMS microbiology reviews*. 2011; 35(5):957–76. [PubMed: 21711367]
19. Houchhut, B.; Dobrindt, U.; Hacker, J. The contribution of pathogenicity islands to the evolution of bacterial pathogens. In: Seifert, HS.; DiRita, V., editors. *The Evolution of Microbial Pathogens*. ASM Press; Washington, D. C.: 2006. p. 83–107.
20. Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: the unseen majority. *Proceedings of the National Academy of Sciences of the United States of America*. 1998; 95(12):6578–83. [PubMed: 9618454]
21. Doran KS, Banerjee A, Disson O, Lecuit M. Concepts and mechanisms: crossing host barriers. *Cold Spring Harbor perspectives in medicine*. 2013; 3(7):a010090. [PubMed: 23818514]
22. Tsukita S, Yamazaki Y, Katsuno T, Tamura A, Tsukita S. Tight junction-based epithelial microenvironment and cell proliferation. *Oncogene*. 2008; 27(55):6930–8. [PubMed: 19029935]
23. McGuckin MA, Linden SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. *Nature reviews Microbiology*. 2011; 9(4):265–78. [PubMed: 21407243]
24. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA. Mucins in the mucosal barrier to infection. *Mucosal immunology*. 2008; 1(3):183–97. [PubMed: 19079178]
25. Gutierrez-Jimenez J, Arciniega I, Navarro-Garcia F. The serine protease motif of Pic mediates a dose-dependent mucolytic activity after binding to sugar constituents of the mucin substrate. *Microbial pathogenesis*. 2008; 45(2):115–23. [PubMed: 18538533]

26. Henderson IR, Czeczulin J, Eslava C, Noriega F, Nataro JP. Characterization of *pic*, a secreted protease of *Shigella flexneri* and enteroaggregative *Escherichia coli*. *Infection and immunity*. 1999; 67(11):5587–96. [PubMed: 10531204]
27. Sonnenburg JL, Xu J, Leip DD, Chen CH, Westover BP, Weatherford J, Buhler JD, Gordon JI. Glycan foraging *in vivo* by an intestine-adapted bacterial symbiont. *Science*. 2005; 307(5717): 1955–9. [PubMed: 15790854]
28. Rasko DA, Rosovitz MJ, Myers GS, Mongodin EF, Fricke WF, Gajer P, Crabtree J, Sebaihia M, Thomson NR, Chaudhuri R, Henderson IR, Sperandio V, Ravel J. The pangenome structure of *Escherichia coli*: comparative genomic analysis of *E. coli* commensal and pathogenic isolates. *Journal of bacteriology*. 2008; 190(20):6881–93. [PubMed: 18676672]
29. Jones B, Pascopella L, Falkow S. Entry of microbes into the host: using M cells to break the mucosal barrier. *Current opinion in immunology*. 1995; 7(4):474–8. [PubMed: 7495510]
30. Wu S, Lim KC, Huang J, Saidi RF, Sears CL. *Bacteroides fragilis* enterotoxin cleaves the zonula adherens protein, E-cadherin. *Proceedings of the National Academy of Sciences of the United States of America*. 1998; 95(25):14979–84. [PubMed: 9844001]
31. Hanakawa Y, Schechter NM, Lin C, Garza L, Li H, Yamaguchi T, Fudaba Y, Nishifuji K, Sugai M, Amagai M, Stanley JR. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. *The Journal of clinical investigation*. 2002; 110(1):53–60. [PubMed: 12093888]
32. Franco AA, Cheng RK, Chung GT, Wu S, Oh HB, Sears CL. Molecular evolution of the pathogenicity island of enterotoxigenic *Bacteroides fragilis* strains. *Journal of bacteriology*. 1999; 181(21):6623–33. [PubMed: 10542162]
33. Yamaguchi T, Nishifuji K, Sasaki M, Fudaba Y, Aepfelbacher M, Takata T, Ohara M, Komatsuzawa H, Amagai M, Sugai M. Identification of the *Staphylococcus aureus* *etd* pathogenicity island which encodes a novel exfoliative toxin, ETD, and EDIN-B. *Infection and immunity*. 2002; 70(10):5835–45. [PubMed: 12228315]
34. Jackson MP, Iandolo JJ. Cloning and expression of the exfoliative toxin B gene from *Staphylococcus aureus*. *Journal of bacteriology*. 1986; 166(2):574–80. [PubMed: 3009410]
35. Jensen VB, Harty JT, Jones BD. Interactions of the invasive pathogens *Salmonella typhimurium*, *Listeria monocytogenes*, and *Shigella flexneri* with M cells and murine Peyer's patches. *Infection and immunity*. 1998; 66(8):3758–66. [PubMed: 9673259]
36. McGuckin MA, Every AL, Skene CD, Linden SK, Chionh YT, Swierczak A, McAuley J, Harbour S, Kaparakis M, Ferrero R, Sutton P. Muc1 mucin limits both *Helicobacter pylori* colonization of the murine gastric mucosa and associated gastritis. *Gastroenterology*. 2007; 133(4):1210–8. [PubMed: 17919495]
37. Vinall LE, King M, Novelli M, Green CA, Daniels G, Hilken J, Sarner M, Swallow DM. Altered expression and allelic association of the hypervariable membrane mucin MUC1 in *Helicobacter pylori* gastritis. *Gastroenterology*. 2002; 123(1):41–9. [PubMed: 12105832]
38. Costa NR, Mendes N, Marcos NT, Reis CA, Caffrey T, Hollingsworth MA, Santos-Silva F. Relevance of MUC1 mucin variable number of tandem repeats polymorphism in *H pylori* adhesion to gastric epithelial cells. *World journal of gastroenterology : WJG*. 2008; 14(9):1411–4. [PubMed: 18322957]
39. Vos HL, de Vries Y, Hilken J. The mouse episialin (Muc1) gene and its promoter: rapid evolution of the repetitive domain in the protein. *Biochemical and biophysical research communications*. 1991; 181(1):121–30. [PubMed: 1958179]
40. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. *Nature reviews Microbiology*. 2008; 6(2):132–42. [PubMed: 18197169]
41. Rooijackers SH, Ruyken M, Roos A, Daha MR, Presanis JS, Sim RB, van Wamel WJ, van Kessel KP, van Strijp JA. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. *Nature immunology*. 2005; 6(9):920–7. [PubMed: 16086019]
42. Rooijackers SH, van Wamel WJ, Ruyken M, van Kessel KP, van Strijp JA. Anti-opsonic properties of staphylokinase. *Microbes and infection / Institut Pasteur*. 2005; 7(3):476–84. [PubMed: 15792635]

43. Del Tordello E, Vacca I, Ram S, Rappuoli R, Serruto D. *Neisseria meningitidis* NaIP cleaves human complement C3, facilitating degradation of C3b and survival in human serum. *Proceedings of the National Academy of Sciences of the United States of America*. 2014; 111(1):427–32. [PubMed: 24367091]
44. Skaar EP. The battle for iron between bacterial pathogens and their vertebrate hosts. *PLoS pathogens*. 2010; 6(8):e1000949. [PubMed: 20711357]
45. Rogers HJ. Iron-binding catechols and virulence in *Escherichia coli*. *Infection and immunity*. 1973; 7(3):445–56. [PubMed: 16558077]
46. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. *Molecular cell*. 2002; 10(5):1033–43. [PubMed: 12453412]
47. Fischbach MA, Lin H, Zhou L, Yu Y, Abergel RJ, Liu DR, Raymond KN, Wanner BL, Strong RK, Walsh CT, Aderem A, Smith KD. The pathogen-associated *iroA* gene cluster mediates bacterial evasion of lipocalin 2. *Proceedings of the National Academy of Sciences of the United States of America*. 2006; 103(44):16502–7. [PubMed: 17060628]
48. Hornef MW, Wick MJ, Rhen M, Normark S. Bacterial strategies for overcoming host innate and adaptive immune responses. *Nature immunology*. 2002; 3(11):1033–40. [PubMed: 12407412]
49. Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R. *Helicobacter pylori* vacuolating cytotoxin inhibits T lymphocyte activation. *Science*. 2003; 301(5636):1099–102. [PubMed: 12934009]
50. Nothelfer K, Arena ET, Pinaud L, Neunlist M, Mozeleski B, Belotserkovsky I, Parsot C, Dinadayala P, Burger-Kentischer A, Raqib R, Sansonetti PJ, Phalipon A. B lymphocytes undergo TLR2-dependent apoptosis upon *Shigella* infection. *The Journal of experimental medicine*. 2014; 211(6):1215–29. [PubMed: 24863068]
51. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. *Nature reviews Microbiology*. 2015; 13(1):42–51. [PubMed: 25435309]
52. Andersen JL, He GX, Kakarla P, K CR, Kumar S, Lakra WS, Mukherjee MM, Ranaweera I, Shrestha U, Tran T, Varela MF. Multidrug efflux pumps from *Enterobacteriaceae*, *Vibrio cholerae* and *Staphylococcus aureus* bacterial food pathogens. *International journal of environmental research and public health*. 2015; 12(2):1487–547. [PubMed: 25635914]
53. Wilson DN, Schluenzen F, Harms JM, Starosta AL, Connell SR, Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105(36):13339–44. [PubMed: 18757750]
54. Feng J, Lupien A, Gingras H, Wasserscheid J, Dewar K, Legare D, Ouellette M. Genome sequencing of linezolid-resistant *Streptococcus pneumoniae* mutants reveals novel mechanisms of resistance. *Genome research*. 2009; 19(7):1214–23. [PubMed: 19351617]
55. Meka VG, Gold HS. Antimicrobial resistance to linezolid. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2004; 39(7):1010–5. [PubMed: 15472854]
56. Frere JM. Beta-lactamases and bacterial resistance to antibiotics. *Molecular microbiology*. 1995; 16(3):385–95. [PubMed: 7565100]
57. Wright GD. Bacterial resistance to antibiotics: enzymatic degradation and modification. *Advanced drug delivery reviews*. 2005; 57(10):1451–70. [PubMed: 15950313]
58. Ochman H, Lawrence JG, Groisman EA. Lateral gene transfer and the nature of bacterial innovation. *Nature*. 2000; 405(6784):299–304. [PubMed: 10830951]
59. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? *Nature reviews Microbiology*. 2010; 8(4):260–71. [PubMed: 20208551]
60. Pukatzki S, Ma AT, Sturtevant D, Krastins B, Sarracino D, Nelson WC, Heidelberg JF, Mekalanos JJ. Identification of a conserved bacterial protein secretion system in *Vibrio cholerae* using the *Dictyostelium* host model system. *Proceedings of the National Academy of Sciences of the United States of America*. 2006; 103(5):1528–33. [PubMed: 16432199]
61. Cascales E, Buchanan SK, Duche D, Kleantous C, Lloubes R, Postle K, Riley M, Slatin S, Cavard D. Colicin biology. *Microbiology and molecular biology reviews : MMBR*. 2007; 71(1):158–229. [PubMed: 17347522]

62. Gagliano VJ, Hinsdill RD. Characterization of a *Staphylococcus aureus* bacteriocin. Journal of bacteriology. 1970; 104(1):117–25. [PubMed: 5473880]
63. Duche D, Parker MW, Gonzalez-Manas JM, Pattus F, Baty D. Uncoupled steps of the colicin A pore formation demonstrated by disulfide bond engineering. The Journal of biological chemistry. 1994; 269(9):6332–9. [PubMed: 8119982]
64. Vankemmelbeke M, Healy B, Moore GR, Kleanthous C, Penfold CN, James R. Rapid detection of colicin E9-induced DNA damage using *Escherichia coli* cells carrying SOS promoter-lux fusions. Journal of bacteriology. 2005; 187(14):4900–7. [PubMed: 15995205]
65. Boon T. Inactivation of ribosomes in vitro by colicin E3 and its mechanism of action. Proceedings of the National Academy of Sciences of the United States of America. 1972; 69(3):549–52. [PubMed: 4551976]
66. Harkness RE, Braun V. Colicin M inhibits peptidoglycan biosynthesis by interfering with lipid carrier recycling. The Journal of biological chemistry. 1989; 264(11):6177–82. [PubMed: 2649496]
67. El Ghachi M, Bouhss A, Barreteau H, Touze T, Auger G, Blanot D, Mengin-Lecreulx D. Colicin M exerts its bacteriolytic effect via enzymatic degradation of undecaprenyl phosphate-linked peptidoglycan precursors. The Journal of biological chemistry. 2006; 281(32):22761–72. [PubMed: 16777846]
68. Olschlager T, Turba A, Braun V. Binding of the immunity protein inactivates colicin M. Molecular microbiology. 1991; 5(5):1105–11. [PubMed: 1956288]
69. Moss JE, Cardozo TJ, Zychlinsky A, Groisman EA. The *selC*-associated SHI-2 pathogenicity island of *Shigella flexneri*. Molecular microbiology. 1999; 33(1):74–83. [PubMed: 10411725]
70. Gerard F, Pradel N, Wu LF. Bactericidal activity of colicin V is mediated by an inner membrane protein, SdaC, of *Escherichia coli*. Journal of bacteriology. 2005; 187(6):1945–50. [PubMed: 15743941]
71. Russell AB, Peterson SB, Mougous JD. Type VI secretion system effectors: poisons with a purpose. Nature reviews Microbiology. 2014; 12(2):137–48. [PubMed: 24384601]
72. Suarez G, Sierra JC, Erova TE, Sha J, Horneman AJ, Chopra AK. A type VI secretion system effector protein, VgrG1, from *Aeromonas hydrophila* that induces host cell toxicity by ADP ribosylation of actin. Journal of bacteriology. 2010; 192(1):155–68. [PubMed: 19880608]
73. Russell AB, Hood RD, Bui NK, LeRoux M, Vollmer W, Mougous JD. Type VI secretion delivers bacteriolytic effectors to target cells. Nature. 2011; 475(7356):343–7. [PubMed: 21776080]
74. Russell AB, LeRoux M, Hathazi K, Agnello DM, Ishikawa T, Wiggins PA, Wai SN, Mougous JD. Diverse type VI secretion phospholipases are functionally plastic antibacterial effectors. Nature. 2013; 496(7446):508–12. [PubMed: 23552891]
75. Koskiniemi S, Lamoureux JG, Nikolakakis KC, t'Kint de Roodenbeke C, Kaplan MD, Low DA, Hayes CS. Rhs proteins from diverse bacteria mediate intercellular competition. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(17):7032–7. [PubMed: 23572593]
76. Fritsch MJ, Trunk K, Diniz JA, Guo M, Trost M, Coulthurst SJ. Proteomic identification of novel secreted antibacterial toxins of the *Serratia marcescens* type VI secretion system. Molecular & cellular proteomics : MCP. 2013; 12(10):2735–49. [PubMed: 23842002]
77. Borgeaud S, Metzger LC, Scignari T, Blokesch M. The type VI secretion system of *Vibrio cholerae* fosters horizontal gene transfer. Science. 2015; 347(6217):63–7. [PubMed: 25554784]

Table 1
Examples of pathogenic mechanisms to evade or overcome selective pressures within the human host

Selective Pressures	Pathogenic mechanisms to evade or overcome these pressures
Physical barriers in host (i.e., mucosal epithelium)	Mucinases Enterotoxins Exfoliative toxins Transcytosis through M cells
Host complement	Complement inhibitor protein C3 protease
Sequestration of host resources (e.g. iron)	Enterobactin/aerobactin systems
Host B- and T-cell lymphocytes	Cytotoxins T3SS-mediated apoptosis
Antibiotics, antimicrobial peptides	Efflux pumps Mutations in antimicrobial targets Enzymes to inactivate antibiotics (e.g. beta-lactamases)
Bacterial colicins	Colicin immunity proteins
Bacterial T6SSs	T6S immunity proteins